Rentracks
6045
D. Western Therapeutics Institute
4576
Wintest
6721
Itamiarts
168A
Migalo Holdings
5535
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.13%177.77B | 15.16%169.87B | -0.81%646.7B | 10.73%170.18B | 5.46%164.4B | -7.16%164.62B | -10.65%147.5B | 2.94%651.97B | -9.41%153.68B | -1.61%155.89B |
Cost of revenue | 3.50%141.11B | -6.61%128.06B | -3.72%551.3B | -1.03%141.07B | -5.04%136.34B | -12.11%136.77B | 4.75%137.13B | 12.11%572.63B | 5.51%142.54B | 5.46%143.58B |
Gross profit | 30.62%36.66B | 302.98%41.81B | 20.24%95.4B | 161.21%29.11B | 127.95%28.07B | 28.24%27.85B | -69.63%10.37B | -35.27%79.34B | -67.75%11.14B | -44.76%12.31B |
Operating expense | 7.49%19.27B | 15.69%18.32B | -4.65%63.7B | -28.84%12.21B | 5.07%17.92B | 6.50%17.73B | -0.64%15.84B | 8.06%66.81B | 3.79%17.16B | 11.56%17.06B |
Operating profit | 71.50%17.39B | 529.76%23.48B | 152.97%31.69B | 380.57%16.89B | 313.70%10.14B | 99.59%10.12B | -129.98%-5.46B | -79.37%12.53B | -133.42%-6.02B | -167.83%-4.75B |
Net non-operating interest income (expenses) | 13.14%-489M | 3.64%-556M | -22.49%-2.17B | -34.87%-468M | -46.61%-563M | 10.17%-565M | -39.37%-577M | -2.37%-1.77B | -14.90%-347M | 24.71%-384M |
Non-operating interest income | 88.10%158M | 150.00%135M | 48.95%353M | 6.09%122M | 95.35%84M | 102.17%93M | 63.64%54M | 99.16%237M | 139.58%115M | 86.96%43M |
Non-operating interest expense | 0.00%647M | 9.51%691M | 25.61%2.53B | 27.71%590M | 51.52%647M | -2.52%658M | 41.16%631M | 8.59%2.01B | 32.00%462M | -19.89%427M |
Net investment income | 280.95%2.47B | -83.60%1.62B | 262.94%10.4B | 198.53%1.42B | 75.39%-1.37B | -77.98%468M | 69.98%9.88B | -9.56%2.87B | -65.28%475M | -882.37%-5.55B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 125.02%268M | 166.64%753M | 747.46%500M | -3,848.00%-987M | -92.00%2M | -219.00%-1.07B | -1.13B | 59M | |
Income from associates and other participating interests | -45.95%928M | 34.74%1.53B | -43.43%3.24B | -143.53%-444M | 48.79%1.72B | -53.65%832M | -35.46%1.13B | 26.10%5.73B | -30.80%1.02B | -2.86%1.15B |
Special income (charges) | -64.71%-1.37B | 210.35%1.58B | -72.06%-6.24B | 62.32%-892M | -28.75%-833M | -589.49%-3.08B | -771.95%-1.43B | -52.57%-3.63B | -56.55%-2.37B | 28.19%-647M |
Less:Other special charges | 64.71%1.37B | -226.15%-1.8B | 0.47%3.64B | -171.95%-1.7B | 28.75%833M | 589.49%3.08B | 771.95%1.43B | 52.57%3.63B | 56.55%2.37B | -28.19%647M |
Less:Write off | --0 | --226M | --2.6B | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Other non-operating income (expenses) | 211.94%418M | 6.42%116M | 150.93%1.35B | -58.10%163M | 209.84%134M | 347.39%944M | 81.67%109M | 174.10%538M | 215.09%389M | 35.11%-122M |
Income before tax | 98.85%19.35B | 659.60%27.77B | 153.77%38.55B | 318.25%17.43B | 195.12%9.73B | -4.55%7.73B | -85.55%3.66B | -76.46%15.19B | -142.68%-7.98B | -240.29%-10.23B |
Income tax | 87.75%4.28B | 301.17%4.81B | 36.84%11.68B | 448.32%6.36B | 39.95%2.28B | -20.88%1.85B | -64.84%1.2B | -26.69%8.54B | -67.93%1.16B | 0.99%1.63B |
Net income | 102.25%15.08B | 835.07%22.96B | 303.79%26.86B | 221.09%11.07B | 162.86%7.45B | 2.06%5.88B | -88.78%2.46B | -87.42%6.65B | -160.58%-9.14B | -308.73%-11.86B |
Net income continuous operations | 102.24%15.08B | 834.73%22.96B | 303.79%26.86B | 221.08%11.07B | 162.87%7.46B | 2.06%5.88B | -88.78%2.46B | -87.42%6.65B | -160.59%-9.14B | -308.69%-11.86B |
Noncontrolling interests | -105.98%-25M | 1,080.46%853M | 147.09%875M | 160.84%261M | 136.16%418M | 163.45%283M | -150.29%-87M | -337.60%-1.86B | -225.00%-429M | -813.58%-1.16B |
Net income attributable to the company | 114.61%15.1B | 769.17%22.1B | 205.36%25.99B | 224.05%10.81B | 165.75%7.04B | -9.85%5.6B | -88.29%2.54B | -83.66%8.51B | -157.24%-8.71B | -293.88%-10.7B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 114.61%15.1B | 769.17%22.1B | 205.36%25.99B | 224.05%10.81B | 165.75%7.04B | -9.85%5.6B | -88.29%2.54B | -83.66%8.51B | -157.24%-8.71B | -293.88%-10.7B |
Gross dividend payment | ||||||||||
Basic earnings per share | 114.53%264.09 | 768.75%386.68 | 205.19%454.71 | 223.99%189.12 | 165.70%123.1 | -9.85%97.98 | -88.29%44.51 | -83.66%148.99 | -157.23%-152.53 | -293.91%-187.36 |
Diluted earnings per share | 114.53%264.09 | 768.75%386.68 | 205.19%454.71 | 223.98%189.1033 | 165.70%123.1 | -9.89%97.9431 | -88.29%44.51 | -83.66%148.99 | -157.23%-152.53 | -293.91%-187.36 |
Dividend per share | 0 | 0 | 0.00%140 | -50.00%70 | 0 | 70 | 0 | 27.27%140 | 27.27%140 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |